Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on LinkedIn:
“As ASCO26 comes to a close, I am reminded once again why the American Society of Clinical Oncology (ASCO) Annual Meeting is such a special gathering for the oncology community.
Beyond the groundbreaking science & new treatment breakthroughs, one of the most rewarding aspects is seeing trainees present their work, reconnecting with friends and colleagues from around the world, and learning from one another in ways that continue to move the field forward. I also greatly valued the opportunity to work with ASCODailyNews to help share emerging, practice-changing data with the worldwide oncology community.
The icing on the cake this year was the breaking presentation of the TALAPRO-3 ph3 trial in metastatic castration-sensitive prostate cancer (mCSPC/mAPMS) with HRR alterations, accompanied by a simultaneous publication in NEJM.
The study demonstrated that adding talazoparib to enzalutamide significantly improved radiographic progression-free survival (rPFS), with an overall hazard ratio of 0.48. Encouraging activity was observed across molecular subgroups, including BRCA, non-BRCA HRR, ATM, and CDK12 alterations.
These findings represent an important step toward more personalized treatment approaches in prostate cancer and may help further expand the role of PARP inhibition in earlier disease settings.
Looking forward to continued progress and, hopefully, regulatory approval in this setting.”